See more : Ichigo Inc. (2337.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cellular Goods PLC (CBX.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellular Goods PLC, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Tern Properties Company Limited (0277.HK) Income Statement Analysis – Financial Results
- Debock Industries Limited (DIL.NS) Income Statement Analysis – Financial Results
- Systematix Corporate Services Limited (SYSTMTXC.BO) Income Statement Analysis – Financial Results
- Artivion, Inc. (AORT) Income Statement Analysis – Financial Results
- Gan & Lee Pharmaceuticals. (603087.SS) Income Statement Analysis – Financial Results
Cellular Goods PLC (CBX.L)
About Cellular Goods PLC
Cellular Goods PLC, together with its subsidiaries, manufactures and sells biosynthetic cannabinoids-based consumer products in the United Kingdom. The company provides cannabinoid solutions for skincare and ingestible products. It offers its products through retailers; direct to consumers through its website; and online. The company was formerly known as Leaf Studios PLC and changed its name to Cellular Goods PLC in September 2020. Cellular Goods PLC was incorporated in 2018 and is based in London, United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 67.24K | 28.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 25.80K | 10.79K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.44K | 18.12K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 61.63% | 62.68% | 0.00% | 0.00% | 0.00% |
| Research & Development | 586.58K | 356.52K | 133.37K | 0.00 | 0.00 |
| General & Administrative | 1.29M | 2.68M | 1.08M | 208.45K | 72.18K |
| Selling & Marketing | 607.50K | 1.93M | 830.23K | 0.00 | 0.00 |
| SG&A | 1.90M | 4.61M | 1.91M | 208.45K | 72.18K |
| Other Expenses | 0.00 | 1.04M | 1.29M | 121.50K | 0.00 |
| Operating Expenses | 3.38M | 6.01M | 3.33M | 329.95K | 72.18K |
| Cost & Expenses | 3.40M | 6.02M | 3.33M | 329.95K | 72.18K |
| Interest Income | 24.11K | 1.30K | 522.00 | 63.00 | 50.00 |
| Interest Expense | 0.00 | 1.30K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 5.00K |
| EBITDA | -3.33M | -5.99M | -3.33M | -329.95K | -72.18K |
| EBITDA Ratio | -4,958.26% | -20,728.13% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.33M | -5.99M | -3.33M | -329.95K | -77.18K |
| Operating Income Ratio | -4,958.26% | -20,728.13% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 24.11K | 1.30K | 522.00 | 63.00 | 50.00 |
| Income Before Tax | -3.31M | -5.99M | -3.33M | -329.89K | -77.13K |
| Income Before Tax Ratio | -4,922.40% | -20,723.63% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 95.00 | -2.60K | -522.00 | -63.00 | -50.00 |
| Net Income | -3.31M | -5.99M | -3.33M | -329.82K | -77.08K |
| Net Income Ratio | -4,922.54% | -20,714.62% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 537.96M | 505.99M | 346.48M | 504.75M | 504.75M |
| Weighted Avg Shares Out (Dil) | 537.96M | 505.99M | 346.48M | 504.75M | 504.75M |
Source: https://incomestatements.info
Category: Stock Reports